These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 791973)

  • 21. Dissolution systems for chloramphenicol tablet bioavailability.
    Ogata H; Shibazaki T; Inoue T; Ejima A
    J Pharm Sci; 1979 Jun; 68(6):712-5. PubMed ID: 37318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
    Gordon MS; Chowhan Z
    Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative bioavailability: eight commercial prednisone tablets.
    Sullivan TJ; Hallmark MR; Sakmar E; Weidler DJ; Earhart RH; Wagner JG
    J Pharmacokinet Biopharm; 1976 Apr; 4(2):157-72. PubMed ID: 950588
    [No Abstract]   [Full Text] [Related]  

  • 24. The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.
    Frey FJ; Rüegsegger MK; Frey BM
    Br J Clin Pharmacol; 1986 Feb; 21(2):183-9. PubMed ID: 3954934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration.
    Center SA; Randolph JF; Warner KL; Simpson KW; Rishniw M
    Res Vet Sci; 2013 Aug; 95(1):225-30. PubMed ID: 23473553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.
    Davis M; Williams R; Chakraborty J; English J; Marks V; Ideo G; Tempini S
    Br J Clin Pharmacol; 1978 Jun; 5(6):501-5. PubMed ID: 656293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring prednisone and prednisolone.
    Jusko WJ; Rose JQ
    Ther Drug Monit; 1980; 2(2):169-76. PubMed ID: 6762710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability and reversible metabolism of prednisone and prednisolone in man.
    Garg V; Jusko WJ
    Biopharm Drug Dispos; 1994 Mar; 15(2):163-72. PubMed ID: 8011967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of food on bioavailability of metronidazole from sugar-coated tablets having different dissolution rates in subjects with low gastric acidity.
    Ogata H; Aoyagi N; Kaniwa N; Ejima A
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):279-82. PubMed ID: 3733276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma concentrations, bioavailability and dissolution of chlorpropamide.
    Taylor T; Assinder DF; Chasseaud LF; Bradford PM; Burton JS
    Eur J Clin Pharmacol; 1977 Mar; 11(3):207-212. PubMed ID: 15845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of plasma prednisolone in man.
    Wilson CG; Ssendagire R; May CS; Paterson JW
    Br J Clin Pharmacol; 1975 Aug; 2(4):321-5. PubMed ID: 1233991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model.
    Wood RW; Martis L; Gillum AW; Roseman TJ; Lin L; Bernardo P
    J Pharm Sci; 1990 Feb; 79(2):124-7. PubMed ID: 2324959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo characteristics of some commercial phenobarbital tablets.
    Sylvestri MF; Ueda CT
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):492-7. PubMed ID: 528095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peristaltic dissolution apparatus: prediction of relative in vivo performance of prednisone tablets in humans.
    Simmons DL; Legore AA; Picotte P
    J Pharm Sci; 1980 Feb; 69(2):220-2. PubMed ID: 7359333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.
    Powell LW; Axelsen E
    Gut; 1972 Sep; 13(9):690-6. PubMed ID: 4639403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Removal of prednisone and prednisolone by plasma exchange.
    Stigelman WH; Henry DH; Talbert RL; Townsend RJ
    Clin Pharm; 1984; 3(4):402-7. PubMed ID: 6467876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of prednisone and prednisolone.
    Pickup ME
    Clin Pharmacokinet; 1979; 4(2):111-28. PubMed ID: 378499
    [No Abstract]   [Full Text] [Related]  

  • 39. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays.
    Meikle AW; Weed JA; Tyler FH
    J Clin Endocrinol Metab; 1975 Oct; 41(4):717-21. PubMed ID: 1176582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone.
    Tanner AR; Caffin JA; Halliday JW; Powell LW
    Br J Clin Pharmacol; 1979 Apr; 7(4):397-400. PubMed ID: 444359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.